Clinical data | |
---|---|
Trade names | Noctamid, Loramet, others |
Other names | Methyllorazepam; Methyl-lorazepam; N-Methyllorazepam; Ro 5-5516 |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Oral, intravenous[1] |
Drug class | Benzodiazepine |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 80% |
Metabolism | Hepatic |
Elimination half-life | 10–12 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.011.546 |
Chemical and physical data | |
Formula | C16H12Cl2N2O2 |
Molar mass | 335.18 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Lormetazepam, sold under the brand name Noctamid among others, is a drug which is a short to intermediate acting 3-hydroxy[3] benzodiazepine derivative and temazepam analogue.[4] It possesses hypnotic, anxiolytic, anticonvulsant, sedative, and skeletal muscle relaxant properties.
It was patented in 1961 and came into medical use in 1980.[5] Lormetazepam is not approved for sale in the United States or Canada. It is licensed in the UK as 0.5 and 1 mg tablets for short-term treatment (2–4 weeks) of moderately severe insomnia. It is licensed in the Netherlands as 1 and 2 mg tablets, under the brand names Loramet and Noctamid and as generic, available from several manufacturers. It is sold in Poland as Noctofer. It is also sold in France as generic as 1 and 2mg tablets, with a maximum prescription duration of 4 weeks. A Dutch analysis stated that lormetazepam could be suitable to be included in drug prescribing formularies, although zolpidem, zopiclone, and temazepam appear better.[6]
analogues
was invoked but never defined (see the help page).